Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Mendus, Audiocast, Q1'26

By Inderes5/8/2026, 12:00 PM
Mendus

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Unknown 1
00:01 - 00:05

Thank you, everybody for joining the Q1 2026 webcast.

Lotta
00:06 - 00:07

Hello, everyone.

Unknown 1
00:09 - 03:19

To start with the summary of Q1, we had a very ambitious plan that we communicated end of last year. And that was based on the positive data that we have documented over time, including the long term follow up. At the end of last year, we presented the ADVANCE II trial that showed long-term survival in MRD-positive, high-risk AML, with nine patients now already beyond five-year survival. So that provided the basis for us to continue the development of the product. We are currently in a trial in a similar setting, but in combination with a drug called oral azacitidine. This is applied after high-intensity chemotherapy. The trial is called AMLM22-CADENCE trial, or in short, the CADENCE trial, for which we wish to recruit 20 patients in the first half of 2026. It's a bit of a bumpy recruitment in AML always. Also in this trial, we are now at 16 patients recruited, and we're still aiming for 20 patients in the first half of this year, which will allow us to do a first readout of the trial; meanwhile, the preparations for the DIVA trial, which is in combination with less intensive first-line treatment of Venetoclax and Azacitidine, are on track. We will also explain in a bit more detail why this is relevant and how this positions us in the AML landscape, and for that trial to support that trial. We have signed a contract with the Olivia Newton-John Cancer Research Institute, which is a leading cancer research institute in Australia. As some of you may know, we are running multiple trials in Australia. And we've therefore also set up a daughter company called Mendus Australia, which is handling not only the practical parts and the trials in Australia, but also allows us to benefit from a very attractive tax incentive that the Australian government allows for companies like us that do their research in Australia. It's not the main reason we do our trials in Australia. The main reason is we can work there with the best people and in this case, particularly Professor Andrew Way, who has been paving the road for post-remission therapies and also for Venetoclax in AML. But it's good to build out our presence in Australia to also allow for the very beneficial circumstances to run these trials. Then, what we have added as an indication to our myeloid blood cancers program is CML. CML is a very large field, roughly ten times bigger than AML, and it's in principle under control with drugs called TKIs or tyrosine kinase inhibitors. But the quality of life of patients can be heavily affected by the continued use of these TKIs. So we have set out the clinical development strategy to position Vididencel as an immunotherapy in CML and help more CML patients accomplish what you call treatment-free remission, where they can live a healthy life without being dependent on day-to-day TKIs. We are very happy that we obtained all the regulatory approvals for the Phase 1 trial to start this program. The VITAL-CML trial, thereby marking the start of the Vididencel clinical development in CML, is now ongoing and has already recruited the first patients in Bergen, in Norway. With that, I'd like to hand it over to Lotta for the financial summary.

Lotta
03:21 - 04:05

Yes. And the financial summary for the quarter was that the costs in the quarter were approximately 20 million Swedish krona, which is 10 million lower than the same period last year. And this is the effect of the reorganization and the cost savings we did for the second half of last year. And this is for the quarter. We have also executed on the first tranche for the loan, which added 30 million to the cash position. The cash position at the end of the quarter is 74 million, compared to 64 million at the end of Q4 2025. That's everything for me.

Unknown 1
04:06 - 15:33

Thanks a lot. And just to reiterate, this is a cash runway that will allow us to reach the end of the year and also the main milestones of our clinical programs. The ongoing clinical programs, starting with AML, are the ADVANCE II trial, which is in long-term follow-up. Again, the patients are doing well. We're very happy with that outcome. Obviously, the AMLM22-CADENCE trial I just described, in combination with oral Azacitidine, is recruiting as we speak; and the DIVA trial, which is in the new first-line treatment setting of Venetoclax plus Azacitidine, is expected to start mid-this year. So we are in full preparation mode now. Also, together with Olivia Newton-John Cancer Research Institute, we aim to have that trial start in a timely way. Combined, the data from these trials and also, of course, keeping a close eye on how the first line landscape in AML will evolve will allow us to set out a registration trial strategy to get this product to market. And very importantly, of course, right now we are positioning the product in the broadest possible way to address patients that have accomplished first complete remission in AML. The CML program started with the VITAL-CML trial. It's a trial that addresses patients with a suboptimal response to the current standard of care, specifically tyrosine kinase inhibitors. But also importantly, we have already prepared for, or are in full preparation mode for, a Phase 2 trial that can start as soon as we have the initial safety data from the Phase 1 trial and actually in parallel. So we also wish to start this trial before the year-end. And this trial will specifically address treatment-free remission, which is the ultimate and most important treatment objective in CML, allowing patients to safely stop their TKI usage. We reported on the ALISON trial, the ovarian cancer trial, at the end of last year. We had presentations at Asco. We had a two-year survival follow-up end of last year. It delivered what it needed to deliver, which was safety and feasibility in this indication. However, ovarian cancer is a quite complex disease. So we think that specifically in relation to the tumor microenvironment which is inherent to this disease, we will need to combine it with other therapeutic modalities. And also with respect to the focus of the company. We have decided to focus on the broader myeloid blood cancer space because it allows us to be very competitive there, in contrast to ovarian cancer. The ovarian cancer competitive landscape is different. And also from the company's perspective, the myeloid blood cancers from now on will be the main focus. But nevertheless, the ovarian cancer program has been successful and we are looking to partner it or to combine it with other therapeutic modalities. Now, to start with the primary concern in AML, and also later explaining how it relates to CML. The only concern in AML is survival. It's such a deadly disease that the first and most important thing is to get it under control. Most patients, unfortunately, relapse and pass away. Despite initial treatment, the survival rate of AML is still 25% or less. With current standard of care. Today, the only curative approach is hematopoietic stem cell transplant. And that's a dangerous procedure which many patients cannot undergo. So the only objective in AML is to make sure patients are able to survive. And what we have done as part of giving patients a bigger platform on our website, we have taken a few patient interviews. This patient called Jacob has taken part in our ADVANCE II trial. And the long story short is the extra life that he experiences now from day to day has allowed him to also see the birth of his grandchild. So this is AML. And with respect to the treatment landscape in AML, there has been for 30-40 years really no change. It's always been high-intensity chemotherapy, which is available for roughly half of the patients. Other half of the patients are considered not fit enough to undergo this intensive chemotherapy. So for the unfit patients, which are patients 75 years and older, or patients that have comorbidities and for which the high intensity chemotherapy is not available, there's now a new drug called venetoclax, which is combined with an injectable form of azacitidine. This first line treatment landscape is shifting, and the reason is that Venetoclax is so successful that it's now also being tested more and more in Fit patients as an alternative to high intensity chemotherapy. And the first randomized controlled data were also presented end of last year at ASH. And what we have seen is that the patients that were treated with venetoclax and azacitidine had a better performance, specifically in the first year as compared to patients treated with high intensity chemotherapy. So we expect a bigger shift towards venetoclax and azacitidine in the AML landscape. And we have adjusted our clinical trial strategy accordingly. In CML, the situation is very different. In CML, the overall survival is very similar to the general population. However, it requires day-to-day targeted treatment of the disease, which is in the form of tyrosine kinase inhibitors or TKIs. The TKIs suppress the disease. But what is very much overlooked is the effect of the TKIs on the quality of life of patients. And these are just two of the interviews that are on our website. The gentleman Giora Sharf is part of a patient organization who really encouraged us to continue and to be part of innovation in CML. And also the young lady called Solveig, who was also in our annual report, indicates how badly the TKIs are affecting her quality of life and how badly she would also like to have a chance of reaching treatment-free remission. So this is in a nutshell, why we do it. The most important part of it is that the immune system, in the end, is also in CML considered to be the key to potential long-term survival without being dependent on tyrosine kinase inhibitors. There is renewed interest in the CML space since the discovery of a new class of TKIs. The TKIs, starting with Gleevec, are already 20 years old in the treatment of CML. They have been developed into second-generation TKIs, but more recently, third-generation TKIs have been developed that have a slightly different mode of action that is more specific for the driver mutation of CML called BCR-ABL, and Novartis, which was the first company to enter the CML space with its TKI called Gleevec, has now also been the first to introduce a new class of TKIs, called allosteric inhibitors, into this space. And they have shown two things. First of all, there is still significant innovation possible in CML, and secondly, it's a very big market that has also resulted in their case in projected peak sales for this product called Asciminib of 4 billion USD. So not surprising. Another compound developed by a company called Terns is now in the hands of another big pharma company called Merck. So Merck is now helping to develop their compound, which is also an allosteric inhibitor, to ultimately challenge the market. So there was a lot of new attention for the CML field. The relevance for us is that these new TKIs that will have deeper and better responses in CML will allow more and more patients to achieve the optimal goal of treatment-free remission, because this state requires a couple of years of continuous deep response. A very deep response on TKIs before you are allowed to stop your TKIs. And when you stop, that's when the disease comes back. And this is where we, with Vididencel, will aim to improve TFR success. So actually, we are dovetailing on the success of these new classes of TKIs and more and more patients reaching these deep molecular responses. So, how do we expand the indication to CML? To expand the indication to CML, you have to start with the Phase 1 trial and show, of course, safety and tolerability. But also, what we have already done is we focus on patients with suboptimal responses to TKI, so that we have embedded in the trial the possibility to observe what happens at the disease level, which is what you call early molecular responses. So all those data will start accumulating since the start of the trial. And we will hope to have the first eight patients already treated to the point that we can have a readout in the second half of the year if the safety is confirmed. We have so far not seen any safety-related issues with our product in the clinical trials, but of course, we need to establish it now in CML. Then we can also start the phase two trial. The phase two trial will focus on patients with a second TFR attempt. It means that they have already failed an earlier TFR attempt, meaning that the disease levels were going up and they had to be restarted on either their existing or new TKI. But if they again reach these very deep remissions and they can do a second TFR attempt, the failure rate is even higher. In the first TFR attempt, it's typically 50% that patients fail within the first 6 to 12 months. In the second TFR attempt, it's typically 75%. So we'll have a good chance of success. Also, in that setting, picking up signals of efficacy relatively early. So this is how the CML trial is now set up. And of course, we're very happy that the VITAL-CML trial is actually ongoing as we speak. So to wrap it up, we have an ambitious clinical development plan that we communicated end of last year. Very importantly, it aligns with the evolving first line treatment landscape in AML, and it will allow us to position Vididencel broadly as a first line post-remission therapy in AML, meaning across all AML subtypes. We are with our immunotherapy approach, not dependent on individual mutations. Also, we will make it independent of the measurable residual disease status, because also patients that have undetectable levels of disease have a high risk of relapse. So already in the cadence trial we are capturing the full spectrum of patients, including patients with undetectable MRD levels. And also we will be after the DIVA trial in a position to combine Vididencel with both high intensity and low intensity first line treatment, being Venetoclax and azacitidine. So we'll basically capture all of the AML patients that successfully achieve a complete remission that will inform our path to market. And we believe that that will be a much more optimal path to market as compared to only one subgroup of patients that we had originally planned for earlier last year. Then the indication and expansion to CML is now in effect. Trials. Trials are ongoing. And the VITAL-CML trial has already recruited the first patients, which positions us for an initial readout already in the second half of 2026, which will then also support the start of the phase two trial. So with that, I'm very excited to report back on the first quarter and happy to take any questions from the audience. Thank you.

Operator
15:35 - 15:52

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Richard Romanus from Redeye. Please go ahead.

Richard Romanus
15:55 - 16:03

Hello. Good afternoon. Just a very quick question. In what quarter do you expect to present the first data from Cadence?

Unknown 1
16:05 - 18:11

Hi Richard. Thanks for joining. The CADENCE trial is a combination of safety, of course, in combination with oral azacitidine, which we formally have to confirm. This is important because oral azacitidine, as you know, has been approved now in the post-chemotherapy setting. So we actually have to show after the single agent ADVANCE II trial that we can safely combine with oral Azacitidine. So that's also the primary objective of the first phase of the CADENCE trial. The second phase will be an expansion phase up to 100 patients. But the first phase is set up to establish safety. But of course, we will also look for initial signs of efficacy. And we can do that also in AML on the molecular disease level. So we are doing MRD measurements, and we can look into how these MRD events evolve before and after treatment. Of course, it's slightly different as compared to the ADVANCE II trial because the ADVANCE II trial focused only on MRD positive patients, whereas the Cadence trial allows any patient to come in independent of MRD status. So it will be a little bit more granular as compared to the ADVANCE II trial, where we immediately already started to see some patients converting from MRD positive to an MRD negative status. This will be a little bit more granular with respect to how MRD evolves over time, but nevertheless, it will give us a good indication about what is happening under the surface. And similarly, and also very similar to what we did in the ADVANCE II trial, we will, of course, look for the response of the immune system, both at baseline and also in correlation with the outcome, with respect to the health of the patients or whether patients relapse or not. But we will also, over time, follow the immune responses that we trigger with Vididencel to make sure that we confirm what we have also seen in the ADVANCE II trial findings, and we can do this after we have incorporated the first 20 patients. It's not black and white, but we have just decided that 20 patients is halfway through the first phase. So it will be a relevant moment to see what is happening as an interim analysis.

Richard Romanus
18:13 - 18:20

Okay, so mid-year when you reached 20 patients, that's when you will present it.

Unknown 1
18:20 - 18:35

Exactly. That's when we need to do the analysis. So around that time, it won't take too long. But one way or the other, of course, we have to first reach the 20 patients, then open the samples, etc. And we will do the analysis. So the most important is first that we get to the 20 patients. And then we do the analysis and we will report shortly afterwards.

Richard Romanus
18:37 - 18:53

Okay. I was wondering in my next question about the recruitment speed across the different trials. How would you compare them from CADENCE to DIVA to the CML trial?

Unknown 1
18:54 - 21:55

It's always difficult to make hard predictions, but I can give you a bit of a sense of the dynamics. So the first line treatment in AML has always been high intensity chemotherapy for roughly half of the patients. Oral azacitidine is now approved. But there's also, of course, patients getting other drugs in that particular setting where we are also combining with oral azacitidine with our product Vididencel. There's also patients going to transplant. There's new trials going on with, for example, a new class of drugs called menin inhibitors. So there's always competitive pressure in the landscape of AML and particularly in the chemo setting, where a lot of people are shifting to venetoclax. To be clear, it has not been approved yet for the chemo fit patients. But you have to think about recruitment in terms of what is going on in the actual clinical development landscape. And there, of course, a lot of the attention has shifted to Venetoclax because it's such a promising drug. So a lot of the combination trials, for example, are also in Venetoclax instead of the high-intensity chemotherapy setting. So this is simply a summary of how the dynamics are with respect to where patients end up. With respect to ongoing clinical trials. And that is of course also why you always need to be on top of your trials and make sure that patients end up in your trial. But in AML, it will never be easy because it's such a tough disease. It's always incident patients. So they are diagnosed with AML. They need immediate treatment and they need to be allocated to your trial or another trial. So the landscape in AML is always quite competitive. And I think this is also why recruitment of the trial is a bit bumpy. We will nevertheless continue, obviously, to make sure that this whole setting, and specifically the safety data in combination with oral azacitidine, is accomplished. The Venetoclax setting is different because there is so much experimenting going on in Venetoclax. We also expect a faster recruitment of the DIVA trial. We have a very ambitious plan to recruit 24 patients in 12 months once the trial has started. So that also gives you a feeling on how the clinical development landscape and the way patients are allocated to trials is currently proceeding. And of course, Andrew Way is a global colleague, but he's also involved in both of these trials. So I think we're making a realistic assessment together with him that the Venetoclax trial will be recruiting quicker and smoother as compared to the Post-chemo trial. With CML, it's different. In CML, instead of incident patients, meaning patients that are newly diagnosed, you have prevalent patients. So these patients are diagnosed, they are under control, and they are on TKIs. So actually it is easier to screen for patients that fit your trial's inclusion criteria. So that's also why, of course, we immediately started recruiting patients after approval. So there I think the recruitment will be more predictable. And that's also why we have a high confidence level. We will be able to report back already on the first eight patients in the second half of this year.

Richard Romanus
21:57 - 22:11

Okay, great. Just one last question. Have you noticed any change in sentiment in business development after the firm's acquisition?

Unknown 1
22:12 - 23:41

It always helps if there is an increased awareness of the possibilities for innovation in the field. And I think for a long time, people have basically, for the wrong reasons, ignored CML because it looks on paper and with respect to the suppression of the disease, to be under control. Right. And now two things have happened. First of all, the launch of Scemblix by Novartis has shown that innovation is still possible in the landscape, and that it will have an impact on quality of life for patients. So that was already a major shake-up for the field. And of course, then you get a lot of other companies also trying to get into that game. And that's only one of them. But it was the one that closely resembles the mode of action of Gleevec. The main thing that has happened is that awareness of CML among pharma companies and investors in the international landscape has grown tremendously. And we think for the right reasons, the main next hurdle, and that's also something that hematologists will tell you if you ask them what is the main objective in the treatment of CML, is actually treatment-free remission. And that is where we are now, of course, also part of that bigger picture and following the path of the TKIs that will lead to more patients becoming TFR eligible.

Richard Romanus
23:45 - 23:47

Okay, great. Thanks for taking my questions.

Unknown 1
23:48 - 23:49

Thanks, Richard.

Operator
23:51 - 23:55

The next question comes from Kian Lee from Pareto. Please go ahead.

Kian Lee
23:57 - 24:25

Hi. Hi. Thanks for the update. Just two questions from me regarding the CML study. So for the patient population being enrolled, could you maybe elaborate a bit more on the characteristics and how the suboptimal response is defined? And the second question is, what kind of molecular response improvement would you consider to be clinically meaningful. Thank you.

Unknown 1
24:26 - 27:07

Jen. First of all, thanks for joining and for your very elegant questions. So I think you need to think about TFR in two ways. First of all, you need to have an optimal response to your TKIs. And it's a scale of scoring, and you need to have at least a four log10 reduction of your disease over many years, depending a bit on the US or Europe, typically 2 to 3 years before you can do a TFR attempt. So if you are a suboptimal responder and you don't reach these very deep levels, you are not even eligible for TFR success. So that means that any patient in our trial that we can, let's say, convert from a suboptimal responder to a more optimal responder is very significant progress. Then of course, you need to establish that the response is sustainable over many years for that patient to actually do a TFR attempt. But it's black and white. If you don't have an optimal response, you will never be eligible for TFR attempt. So that's why we are so keen to combine the safety and tolerability data with also the early molecular responses that we may be able to detect in some of these patients, which will lead to a deeper response as compared to their earlier lines of treatments with TKIs. In the end, for the patients, the most relevant phase is obviously to have a real TFR attempt and to have that attempt be successful. Now, if you look into the subpopulations of patients, the suboptimal responders represent roughly 20 to 30% of the people in the chronic phase of CML treatment. The other, let's say more optimal responders, they could in principle all be eligible for TFR attempt. So that is, I think, also a portion of patients that will grow with the new classes of TKI. So that is the majority of the market. It's just that because of the TFR failure rates are so high, it takes, first of all, a long time to become TFR eligible. And then if you stop and you fail to clear out the disease, and that's visible already in the first 6 to 12 months, then of course, you have to wait for another couple of years before you can do a second TFR attempt. And that is really holding down the TFR success rate. So, if you look over a period of ten years since diagnosis, only 25% of patients successfully achieve TFR. And that is the bigger pool of patients, obviously, that we zoom in on.

Kian Lee
27:10 - 27:12

Okay. Thank you so much. That's all for me.

Unknown 1
27:13 - 27:14

Thanks, Jen.

Operator
27:17 - 27:29

As a reminder, if you wish to ask a question, please dial pound key five on your telephone keypad. The next question comes from Aaron Achkar from Edison Group. Please go ahead.

Aaron Achkar
27:32 - 27:55

Good afternoon and thanks for the update and thanks for taking my questions. First of all, I wanted to ask about the operating income relating to the research collaboration with the biopharma partner. I'm just curious to know if you're able to share any details there. And if not, then maybe when we might expect an update. And then similarly, can we expect a similar run rate for this other operating income throughout the year?

Unknown 1
27:57 - 28:34

Yeah. So let me start with your first question, Aaron, about the collaboration. It is ongoing. And the partner you work with has moved their part of the program into the clinic now. And I expect we may be able to speak in more detail about this program in the second half of this year. We are still in an early stage. We want to make sure that the collaboration continues and also moves into the next phase of the collaboration. So we hope to be able to say a bit more, with permission of our partner, in the second half of this year. And what was your question with respect to the operating cash flow?

Aaron Achkar
28:36 - 28:46

So, the other operating income this year relating to that partner, can we expect a similar run rate throughout the year for the subsequent quarters?

Unknown 1
28:47 - 29:16

You mean related to the collaboration? Right now, the only thing related to income is the fact that they pay for the program, right? Clinical program. It may shift, of course, to a bigger collaboration if successful. But that's also why we have been quite modest. And also the partner was not really keen on sharing the details of that program. But since it's now in the clinic, we are talking with them that we can maybe say a bit more about it in the second half of the year.

Aaron Achkar
29:18 - 29:39

Okay. Perfect. Thank you. And then my next question relates to manufacturing. And we've seen that that's been a key differentiator for Vididencel over the years. And then large-scale GMP production now set up with NorthX Biologics, so it would be good to know if there are any other additional manufacturing milestones or similar that we can be watching out for in the years to come.

Unknown 1
29:41 - 30:58

Well, the most important thing is that we have established it, Aaron. And that's not only, let's say the, uh, physical part of the process, which is that you do what's called a technology transfer from your non-gmp setting, uh, which is in our case, our labs in Leiden to a GMP setting, which is the facilities of, of north Sweden. But also that you document it all properly and that you have continued contact with the regulators, that the way you have scaled up your process is in line with their expectations and also a basis to continue clinical development. And in the end, market registration without hiccups concerning product changes or alterations in the manufacturing process. So that is what we are constantly working on. So it's not only the making of the batches, because we have made enough material to support our current planned trials. So for future trials, we will continue to manufacture more. And it's also good for the collaboration and keeping the teams trained from both sides that the manufacturing continues, but it's not factually necessary right now to continue to manufacture more because we have actually established the process. And also, like I said, enough material for the currently planned and ongoing trials. But it is of course a collaboration that we want to keep active.

Aaron Achkar
31:00 - 31:09

Okay. That's helpful. Thank you. I did have one more question about recruitment relating to CADENCE, but I think you addressed that above actually. So nothing else from me. Thank you.

Unknown 1
31:10 - 31:11

Thanks for participating, Aaron.

Operator
31:16 - 31:23

There are no more questions at this time. So I hand the conference back to the speakers for any written questions and closing comments.

Unknown 1
31:24 - 32:26

So I looked into the activity feed, and there was one message from somebody participating, asking what the main purposes of Vididencel for CML are for improving the TFR rate, so I hope I addressed that. It's indeed improving the TFR rate and in two ways. First of all, making more patients eligible for a TFR attempt by deepening their response that was suboptimal to TKIs. And secondly, and most importantly, of course, to sustain those TFR. And that's particularly relevant for the patients that have accomplished TFR eligibility and just need a much better outcome of their TFR attempt. And what can we expect in this trial? I think I've alluded to that. And then there was also one written email we received prior to the presentation starting via our email address. And that was about the partnering and the way the CML landscape is shaping up. I think I have addressed those questions in the answers to the people that were on the call. So with that, I would like to conclude this Q&A and also thank everybody for their participation.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…